Innovent Biologics

Happy spring! Our China campus is blooming with cherry blossoms, a beautiful reminder of renewal and growth. Just as these delicate flowers emerge with precision and purpose, our biotech innovations are advancing to create healthier futures. Nature's rhythms inspire our own scientific journey—carefully nurturing potential until it flourishes. We're grateful to be rooted in this vibrant community and invite you to connect with us as we grow together toward better healthcare solutions for all. #InnoventBiologics

Innovent delivered a strong performance in 2024, with revenue up 51% to RMB 9.4B, EBITDA turning positive, and losses narrowing. Our CFO, Rachel You, sat down with Hong Kong's Now Finance to discuss the key drivers behind this growth: ✅ TYVYT® Revenue Growth – Contributing ~RMB 4B, driven by strong brand recognition and deeper market penetration. ✅ Margin Expansion – Economies of scale and production efficiency improvements are sustaining gross margins above 80%. ✅ Future Growth – New TYVYT® indications in the pipeline signal continued momentum. ✅ Pipeline Progress – Advancements in both early-stage and key late-stage assets are laying the foundation for new product launches in 2025. Adding to our success, in just 14 years, Innovent has launched 15 new drugs, benefiting 3.5 million patients—a testament to our commitment to innovation and patient impact. Proud of our team's execution and strategic focus! Watch the full interview (in Mandarin/Cantonese) here: Part1：https://lnkd.in/g9QgaUHW Part2：https://lnkd.in/ggPs34NE

A year of innovation and growth! Explore Innovent's 2024 Annual and Financial Report through this video, highlighting our achievements, financial performance, and vision for the near future:

We're proud to share that Innovent's IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, has received Breakthrough Therapy Designation from China's NMPA for the treatment of unresectable mucosal or acral melanoma. With the first patient dosed in its pivotal study and two Fast Track designations from the U.S. FDA, IBI363 is advancing as a promising immunotherapy candidate.  https://lnkd.in/gY5ZngES #InnoventBiologics #Oncology

Our team will be presenting preclinical data on multiple novel bispecific antibodies and antibody-drug conjugates (ADCs) from our oncology pipeline at the upcoming #AACR25 this April. The presentations will include two late-breaking research sessions and several poster sessions. We look forward to sharing our latest innovations with the global cancer research community! Find us here: https://lnkd.in/gd8Y-vs4 #InnoventBiologics #Oncology

We're proud to share our 2024 annual results, marking a milestone year of profitability and strong growth. With revenue reaching new heights and a clear path toward our RMB20bn sales target by 2027, we continue to drive innovation in oncology and expand into cardiovascular and metabolic medicine. Key highlights: 🔹 Six new product launches anticipated in 2025, strengthening our oncology portfolio and CVM commercialization 🔹 Next-gen R&D, with five assets targeting global Phase 3 by 2030 🔹 Global expansion, including a new Shanghai R&D center, U.S. lab, and expanded manufacturing 🔹 Sustainable growth, with an AAA ESG rating and deepened commitment to patient support With science, innovation, and sustainability at our core, we're poised for long-term impact well beyond the coming years. Thank you to our employees, partners, and investors for your continued trust and collaboration. Together, we are shaping the future of global healthcare. Read more: https://lnkd.in/dhFRf39v

We are pleased to announce that the first participant has been successfully dosed with our HER2 antibody-drug conjugate, IBI354, in the HeriCare-Ovarian01 Phase 3 clinical trial for platinum-resistant ovarian cancer with HER2 expression. This randomized, controlled, multicenter study is the first Phase 3 trial in China to evaluate PROC with HER2 expression. Ovarian cancer is a leading cause of gynecological cancer-related deaths, with limited options for platinum-resistant cases. About 38% of patients have HER2 expression, yet no anti-HER2 therapies are approved in China. In a prior Phase 1/2 study, IBI354 showed an excellent safety profile and promising activity, including in heavily pretreated patients. We look forward to advancing this research and bringing hope to those affected by this challenging disease. https://lnkd.in/gcXQ_Fak #InnoventBiologics #Oncology

We are happy to share that the FRUSICA-2 Phase 2/3 trial has met its primary endpoint, demonstrating improved progression-free survival (PFS) with sintilimab plus fruquintinib as a second-line treatment for metastatic renal cell carcinoma (RCC) in China. This progress underscores the clinical strength and durability of sintilimab as an immune checkpoint inhibitor and reflects our commitment to expanding its therapeutic potential. We sincerely thank our partner, 和黄医药, for their collaboration in advancing this important research. This milestone builds on the NMPA's conditional approval of the combination for advanced endometrial cancer, based on FRUSICA-1. Together, we will continue to drive innovation in oncology and deliver impactful treatment options to patients in need. https://lnkd.in/dpBTMAC6 #InnoventBiologics #ClinicalTrials #Oncology

Colorectal cancer is the second leading cause of cancer deaths in the U.S. and a growing concern in China, where incidence rates are among the highest worldwide. While screening can detect precancerous polyps and early-stage cancers, cases continue to rise—especially among individuals under 50. Early detection is one of the most effective ways to improve outcomes. At Innovent, we are dedicated to developing new treatment options for advanced colorectal cancer. Our investigational therapy, IBI363, is designed to enhance T-cell activation while minimizing toxicity, showing promising early results in clinical studies. If you're eligible for screening, don't wait—early detection saves lives. Learn how to reduce your risk of colorectal cancer here: https://lnkd.in/eFhM8_sx #ColorectalCancerAwarenessMonth #Oncology #InnoventBiologics

For the first time in 70 years, a new treatment is available for thyroid eye disease (TED) in China. SYCUME® (teprotumumab N01, IGF-1R), developed by Innovent, has been approved by the NMPA, making it China's first and the world's second IGF-1R antibody drug. TED is a serious autoimmune disease that can cause proptosis, vision impairment, and significant quality-of-life challenges. Until now, treatment options in China have been limited and often inadequate. SYCUME® offers a long-awaited, effective solution, setting a new standard of care for patients. This approval marks a major milestone in Innovent's mission to drive medical innovation and expand access to breakthrough therapies. It is backed by strong clinical evidence from the Phase 3 RESTORE-1 study, which met its primary endpoint in 2024. The results showed that 85.8% of patients achieved a ≥2 mm reduction in proptosis at Week 24, along with significant improvements in inflammation and overall quality of life. #InnoventBiologics https://lnkd.in/gGpWAqsi